CK2 inhibition has an antileukemia effect in vitro and in vivo. (A) In vitro inhibition of cellular proliferation in Nalm6 cells following treatment with the CK2 inhibitor CX-4945. B-ALL cells were treated with increasing doses of CX-4945, and cell proliferation was measured by WST-1 assay over time. (B) Effect of Ikaros knockdown on CX-4945–induced suppression of cell proliferation in Nalm6 cells. Graphed data in A-B are the mean ± standard error of the mean of triplicates from 1 experiment, representative of 3 independent experiments. (C-E) Antileukemia effects of CK2 inhibition in the Nalm6 human-mouse xenograft. (C) Representative images and (D) quantification of leukemia progression measured by in vivo bioluminescence in mice treated with the CK2 inhibitor, CX-4945, and in vehicle controls. (F) Human-mouse xenografts established with Nalm6 B-ALL cells were treated for 7 days with the CK2 inhibitor, CX-4945, or vehicle control, and survival was followed. Survival curves were generated using the Kaplan-Meier method, and differences in survival were analyzed by χ2 test. Comparisons in A-B and D were by Student t test. **P ≤ .01; ***P ≤ .001.
